LeMaitre Vascular Posts Strong Q4 2025 Growth, Raises Dividend
Event summary
- Q4 2025 sales reached $64.5 million, up 16% year-over-year, with 15% organic growth.
- Gross margin expanded by 240 basis points to 71.7%, driven by higher ASPs and manufacturing efficiencies.
- Operating income surged 47% to $18.8 million, with an operating margin of 29%.
- Quarterly dividend increased by 25% to $0.25 per share, effective March 26, 2026.
- 2026 guidance projects 12% sales growth to $280 million and 21% adjusted operating income growth to $77.8 million.
The big picture
LeMaitre Vascular's strong Q4 2025 results reflect its strategic focus on international expansion and operational efficiency. The company's ability to drive double-digit sales growth and margin expansion positions it favorably in the competitive vascular devices market. The dividend increase underscores its commitment to returning value to shareholders, but sustaining this momentum will require continued execution in key markets.
What we're watching
- International Growth
- The pace at which EMEA and APAC regions sustain their high growth rates will be critical for LeMaitre's continued expansion.
- Operational Efficiency
- Whether LeMaitre can maintain its gross margin expansion amid potential cost pressures will impact profitability.
- Dividend Sustainability
- How the company balances dividend increases with reinvestment in growth initiatives will be a key focus for investors.
Related topics